This study aimed to examine the association of fetal growth and elevated third trimester maternal serum folate due to folic acid (FA) supplement intake. Dietary intake, use of FA supplements, weight, and blood biomarkers of B-vitamins (serum folate, pyridoxal, vitamin B 12 , and plasma total homocysteine) were observed in 33 healthy pregnant women at the third trimester (average gestational age 35 wk). Birth outcomes were assessed through hospital birth records. Infant anthropometry and maternal blood biomarkers were followed up at 1 mo postpartum. Fourteen women were taking FA supplements at the third trimester. Dietary intake was similar among FA users and non-users, but serum folate and pyridoxal were significantly higher in users (11.6 Ϯ 6.7 vs. 6.1 Ϯ 3.2 ng/mL, and 13.8 Ϯ 21.7 vs. 3.2 Ϯ 1.4 ng/mL, respectively). Plasma total homocystein (tHcy) was higher in non-users compared to users, but not significantly. Nine FA users and eight non-users had low serum vitamin B 12 values ( Ͻ 203 pg/mL). Nine FA users and all non-users had low serum pyridoxal values ( Ͻ 7.0 ng/mL). Infant birthweight was significantly lower in users compared to non-users (2,894 Ϯ 318 vs. 3,154 Ϯ 230 g). At 1 mo postpartum, infant weight and length were similar between FA users and non-users, but infant weight gain was larger in users. Higher serum folate values due to FA use in the third trimester was related to reduced fetal size. Excess FA under low vitamin B 6 and B 12 status may affect fetal growth. Key Words pregnancy, folate, supplement use, birthweight Periconceptional folic acid (FA) supplements are currently recommended to women planning pregnancy, to avoid fetal neural tube defects (NTDs) ( 1 ) in Japan, and many other countries ( 2 ). Before its effect on NTD prevention was found, FA supplementation was previously known for its effect in preventing anemia in pregnancy ( 3 , 4 ). However, a number of recent studies have focused on other relations of folate to pregnancy health, such as pregnancy-induced hypertension ( 5-8 ), placental abruption ( 9 ), fetal growth restriction ( 10 ), and preterm birth ( 11 ), suggesting extended FA supplementation to reduce risks for these adverse pregnancy outcomes. While FA supplementation throughout pregnancy has been considered safe, concerns are arising on the long-term health effects of synthesized folate on infant health. Excess FA may induce changes to the genetic expression of the fetus, such as observed in animal experiments ( 12 , 13 ). This may pose lifetime changes to the health status of the offspring.
Periconceptional folic acid (FA) supplements are currently recommended to women planning pregnancy, to avoid fetal neural tube defects (NTDs) ( 1 ) in Japan, and many other countries ( 2 ) . Before its effect on NTD prevention was found, FA supplementation was previously known for its effect in preventing anemia in pregnancy ( 3 , 4 ). However, a number of recent studies have focused on other relations of folate to pregnancy health, such as pregnancy-induced hypertension ( 5-8 ), placental abruption ( 9 ), fetal growth restriction ( 10 ), and preterm birth ( 11 ), suggesting extended FA supplementation to reduce risks for these adverse pregnancy outcomes. While FA supplementation throughout pregnancy has been considered safe, concerns are arising on the long-term health effects of synthesized folate on infant health. Excess FA may induce changes to the genetic expression of the fetus, such as observed in animal experiments ( 12 , 13 ). This may pose lifetime changes to the health status of the offspring.
Folate is an essential component in various metabolic processes, such as one-carbon transfer reactions including formate oxidation, amino acid metabolism and biosynthesis of thymidylate and purines ( 14 ). In regenerating methione from homocysteine, methionine synthase catalyzes the cobalamin-dependent transfer of a methyl group from 5-methyl-tetrahydrofolate. Homocysteine is also catalyzed into cysteine through the transsulfuration pathway, which involves cystathionine ␤ -synthase which is dependent on pyridoxal phosphate. Therefore, deficiency of either folate, vitamin B 12 , or vitamin B 6 E-mail: thidemi@niph.go.jp will alter homocysteine metabolism, resulting in hyperhomocysteinemia. However, blood homocysteine values are reported to decline in pregnancy compared to nonpregnant status, even under poor folate, vitamin B 12 , or vitamin B 6 status ( 15 , 16 ). As this decline is observed in FA users and non-users alike, and is not related to hemodilution, it is speculated that endocrine changes due to pregnancy are the cause ( 17 ). Thus, it is essential to measure all biomarkers related to homocysteine metabolism, to accurately determine maternal nutritional status of folate, vitamin B 12 , or vitamin B 6 .
We have previously reported that dietary folate intake in predominantly unsupplemented Japanese women was 271-284 g/d throughout pregnancy ( 18 ), which did not meet the then recommended intake of 440 g/d ( 19 ) . In spite of their low folate intake, folate deficiency as determined by red cell folate value was 9% and 22% for the second and third trimesters. More than 5 y have passed since our last study, and recent reports estimate that FA supplement use has increased to about one-third of pregnant women ( 20 , 21 ) . In order to determine the association of FA supplementation in late pregnancy to infant health, we conducted a longitudinal survey on third trimester pregnant women to 1 mo postpartum, through the examination of their dietary intake, FA supplement use, blood B-vitamin status (serum folate, vitamin B 6 , B 12 , and plasma total homocysteine), and infant outcomes.
METHODS
Study subjects. The study subjects were originally recruited to participate in a dietary advice program, starting before 18 wk gestation to the third trimester. Forty-two healthy pregnant women attending an obstetric department in central Tokyo were invited to participate, from December 2007 to September 2008. No women had major complications such as diabetes or hypertension. Dietary advice was given individually to all women based on their daily dietary records, through trained dieticians. No specific comments were given regarding the use of dietary supplements, so the woman's intent to take supplements was not influenced by the program. All women were carrying a single fetus. Each woman was given detailed oral and written information regarding the study protocol and signed an informed consent form.
The women completed a questionnaire regarding parity, self-reported height, pre-pregnancy weight, measured current weight, dietary habits, current supplemental use of vitamins and minerals, and drinking and smoking habits at the third trimester. A 24-h dietary recall survey was applied for the estimation of dietary intakes. Non-fasting venous blood samples were drawn from each woman for the measurement of blood biomarkers on the same day as the dietary survey. Infant birth anthropometry and delivery status was obtained from the hospital delivery records. At 1 mo postpartum, all infants were weighed and measured by hospital nurses.
One woman experienced abortion before the third trimester, one moved to another hospital, and four women were unavailable at the third trimester due to admission to inpatient care because of premature uterine contractions. Three women failed to participate in the postpartum survey. The data on 33 women complete with records at the third trimester, birth, and 1 mo postpartum were used for the analyses in this study. Dietary assessments. Participants were asked to complete a 24-h dietary recall survey to estimate their dietary nutrient intake at the third trimester. The daily intake of individual nutrients was calculated using the Standard Food Composition Table ( 22 ) , where food folate content was measured by Lactobacillus rhamnosus microbiological assay after treatments with protease and folate conjugase. As grain products are not fortified with folic acid in Japan, the intake of FA was estimated to be restricted only to supplements. Participants were requested to recall the brand or type of supplements they had taken on the recalled day. Based on this information, subjects were identified as FA users or nonusers. Although the exact FA content of the supplements was unavailable, the intake of FA was estimated to be 200-400 g/d. All participants were requested to also recall the use of supplements at the first and second trimesters. FA use was not identified at 1 mo postpartum, as FA use is not currently recommended during lactation.
Blood samples and laboratory analysis . Non-fasting blood samples were obtained at the third trimester for the measurements of serum folate, pyridoxal, vitamin B 12 , and plasma total homocysteine (tHcy). Plasma and serum samples were separated from whole blood collected into tubes containing EDTA-2Na and those without any anticoagulant, respectively. All blood samples were stored at Ϫ 80˚C until measurements. Chemiluminescent immunoassay was used for the measurements of serum folate and vitamin B 12 . High performance liquid chromatography (HPLC) with the fluorescent-detection method was used for the measurement of plasma tHcy ( 23 ) . HPLC method was also used in the measurement of serum pyridoxal.
Statistical analysis . The data were expressed as mean Ϯ SD where appropriate. Mann-Whitney's U -tests were applied to compare continuous variables between FA users and non-users, and chi-square tests were applied for categorical variables. Wilcoxon's signed rank tests were used to compare continuous variables between the third trimester and postpartum. Spearman's correlation coefficients were used to examine the correlations between dietary intake data, blood biomarkers and maternal and infant anthropometry. Multiple regression analyses were applied to examine the effect of third trimester dietary intakes and blood biomarker values to birth anthropometry. A p value of less than 0.05 was considered significant. All analyses were performed using the SPSS 15.0-J statistical package program (SPSS, Tokyo, Japan).
The study was conducted according to the Declaration of Helsinki. The study design and protocols of this study were approved by the Ethics Committee of Tokyo
Medical and Dental University.
RESULTS

General characteristics, dietary intakes and blood biomarkers in FA supplement users and non-users
Maternal characteristics, dietary intake status, and blood biomarker status in FA users and non-users at the third trimester are shown in Table 1 . Twenty-nine women were primiparas. There were two multiparas each in both FA users and non-users. All women were non-smokers. Subjects' age, height, pre-pregnancy weight, body mass index (BMI), weight gains, and gestational age at survey were similar. In FA users, 6 women reported FA use at both first and second trimesters. Three women reported not taking FA supplements in the first and second trimesters, but reported FA use at the third trimester. In non-users, 4 women reported FA use in the first trimester. In all, 15 women reported no use of FA supplements, 4 women reported use only at the first trimester, two reported use in the first and third trimesters, three reported use in the second and third trimesters, three reported use only in the third trimester, and six reported use at all three trimesters. There was no significant difference in dietary nutrient intakes, but FA users had a significantly lower intake of dark colored vegetables ( p ϭ 0.04). Serum folate and pyridoxal showed a significant difference between the two groups, which was markedly higher in FA users compared to non-users (both p Ͻ 0.05). Plasma tHcy was higher in non-users compared to users, but the difference was Table 2 . Eight women delivered by cesarean section, three in FA users and five in nonusers. There were 8 boys in FA users and 10 in nonusers. Both maternal weight at delivery and weight gains during pregnancy were similar between FA users and non-users. Significant differences in birth outcomes were observed. Gestational length was significantly lower in FA users compared to non-users The association of dietary intakes of vitamin B12, fruit juice, and fish/marine products, period of FA use, and the four blood biomarkers to infant birth anthropometry were examined through multiple regression analyses, using the STEPWISE method to select significant factors. Period of FA use was not selected as a significant factor in the STEPWISE analysis. As shown in Table 3 , higher intake of fish/marine products was significantly associated with higher birthweight, and higher intake of dietary vitamin B12 was significantly associated with infant length. Higher serum folate value was associated with both decreased birthweight and head circumference.
At 1 mo postpartum, all infants were breastfed either exclusively or partially. Maternal weight, BMI, infant The Spearman's correlation coefficients between each blood biomarker value for FA users and non-users were examined. In FA users, serum folate was not correlated to the other three biomarkers. Only serum pyridoxal was significantly correlated to plasma tHcy (RϭϪ0.60, pϭ0.04). In non-users, serum folate value was negatively correlated to plasma tHcy (RϭϪ0.69, pϽ0.01), but not to serum pyridoxal or vitamin B 12. Serum pyridoxal was negatively correlated to plasma tHcy (RϭϪ0.56, pϭ0.02), but vitamin B12 was not.
DISCUSSION
Since the folate recommendation was issued in 2000 (1), information on periconceptional folate has been distributed to Japanese young women through TV programs, magazine articles, websites, and the Maternal and Child Health Handbooks. Due to these intersectoral efforts, the proportion of supplement users in pregnant women has increased (20, 21, 24) . As there are no current guidelines on whether or not to continue FA use after 12 wk gestation, there is concern among obstetricians and pregnant women. Of special concern is the health consequence for the developing fetus.
Maternal pre-pregnancy folate status and the timing, dose, duration, and method of FA supplementation in pregnancy seem to be key factors determining the effect of FA on fetal growth. In a landmark trial by Baumslag et al. (25) , 5 mg of daily FA supplementation after 28 wk was only effective in increasing the birthweight of Bantu women, whose daily folate intake was low compared to that of white women with frequent consumption of fruits and vegetables. In another trial conducted in Nepal, women were supplemented daily with 0.4 mg FA from about 11 wk to delivery. However, supplemented women did not have heavier babies compared to controls, but rather had slightly shorter (Ϫ0.32 cm) babies (26) . In a UK trial, pregnant women were supplemented daily with either 0.2 mg or 5 mg FA, from about 17 wk to delivery. There was no difference in birthweight in either group, compared to nonsupplemented controls (27) . Furthermore, mandatory FA fortification of grain products in the US seems to have had little impact on the prevalence of low birthweight. Low birthweight has increased since 2000, from 6.00% to 6.49% in 2006 (28) .
Our present results are contrary to our previous study on non-supplemented women, which demonstrated that elevated plasma tHcy, which was suggestive of folate inadequacy, was related to lower birthweight (Ϫ151 g for per mol/L increase) (18). The difference between the current and prior study subjects was the prevalence of low serum vitamin B12. More than half of the current study subjects (17 women) had low serum vitamin B12 values at the third trimester, compared to 16% in the previous study. In order to identify whether low serum vitamin B12 during pregnancy was associated with deficiency, or was due to physiological changes in pregnancy, measurement of serum methylmalonic acid should have been conducted (29) . Another concern is the highly prevalent vitamin B6 deficiency during pregnancy. Nearly all women had low serum pyridoxal values (Ͻ7.0 ng/mL) at the third trimester, and 15 women (45.5%) had low values postpartum. A prior study on pregnant Japanese women reports a high prevalence of low pyridoxal values (30) . Homocysteine levels are reported to be lower in the umbilical artery compared to those in the umbilical vein, suggesting its active uptake by the fetus (31) . As folate, vitamin B 6, and B12 are all essential components in homocysteine metabolism (14), we speculate that the excess intake of one vitamin under the deficiency of another may alter the metabolic pathways, which may impair fetal growth. A previous study on 11 Irish newborns detected unmetabolized FA in their cord blood, though mothers had taken FA only through fortified foods (32) . It suggests that such low levels of FA intake may affect the folate metabolism of the fetus.
Our result on the positive association of fish intake and birthweight is consistent with previous reports on increased maternal fish intake and higher birthweight (33) (34) (35) , which attributes n-3 fatty acids to enhanced fetal growth. On the other hand, higher fish consumption is a risk factor for fetal exposure to methyl-mercury, which may be detrimental to the neurological development of the infant (36) . However, recent studies suggest that by selecting "lean" fish, fish consumption could be safe and also beneficial for enhancing infant development (37, 38) .
The difference in weight among infants from FA users and non-users observed at birth was no longer significant at 1 mo. Although not statistically significant, infants born to FA users had gained more weight. Early postnatal catch-up growth has been reported to be a risk factor for insulin resistance (39) or elevated blood pressure (40) in later life. Furthermore, infants with growth faltering in the third trimester have shown more catch-up growth in the first 6 wk of life, which was related to increased fat mass at 6 mo (41) . The altered intrauterine growth observed in infants born to FA users may expose them to higher risks for chronic diseases.
To date, studies regarding folate status in pregnancy have been mostly focused on deficiencies, not excess. To our knowledge, only a few human studies concerning pregnancy folate status and long-term health influences have been conducted. In an epidemiological study conducted in India, children born to mothers with higher erythrocyte folate concentrations but low serum vitamin B12 values during pregnancy had a higher rate of insulin resistance and adiposity at 6 y of age (42) . Furthermore, there are two studies which evaluated the association between FA supplementation or maternal serum folate and childhood asthma or respiratory health in early infancy (43, 44) . These studies indicated that supplementary FA intake was associated with increased risk of childhood asthma or wheezing during infancy.
Periconceptional FA supplementation policies have been implemented worldwide (2), but the possible side effects on short-and long-term infant health have yet to be examined. The limitation of this study was its small sample size (nϭ33). The proportion of low birthweight was higher (14.2%) in FA users compared to non-users (0%), though not statistically significant (pϭ0.09 by chi-square test). This proportion of low birthweight in our FA users is unexpectedly high compared to the national data, which is about 9% including preterm births (45) . Both low birthweight infants were born to mothers who had taken FA supplements throughout pregnancy, but we could not determine whether the cause was due to longer FA use. Further investigation on a larger scale is needed to identify the possible adverse effect of high FA intake on both fetal wellbeing and long-term infant health. Moreover, further studies on the fish consumption patterns of pregnant women should be done to safely recommend fish intake to promote pregnancy health. 
